Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC

BACKGROUND: RECORD-3 compared everolimus and sunitinib as first-line therapy, and the sequence of everolimus followed by sunitinib at progression compared with the opposite (standard) sequence in patients with metastatic renal cell carcinoma (mRCC). This final overall survival (OS) analysis evaluate...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Ann Oncol
Main Authors: Knox, J. J., Barrios, C. H., Kim, T. M., Cosgriff, T., Srimuninnimit, V., Pittman, K., Sabbatini, R., Rha, S. Y., Flaig, T. W., Page, R. D., Beck, J. T., Cheung, F., Yadav, S., Patel, P., Geoffrois, L., Niolat, J., Berkowitz, N., Marker, M., Chen, D., Motzer, R. J.
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2017
Assuntos:
Original Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5452072/
https://ncbi.nlm.nih.gov/pubmed/28327953
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdx075
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares